Elicio Therapeutics, Inc. announced on March 24, 2025, the appointment of Preetam Shah, Ph.D., MBA, as its new Chief Strategy and Financial Officer. Dr. Shah's appointment is effective immediately and brings significant leadership experience to the company's executive team.
Dr. Shah previously served in senior leadership roles, including chief financial officer and chief business officer, at multiple publicly traded biotechnology companies. His background includes overseeing corporate financings, business development transactions, and guiding corporate strategy.
His expertise in corporate finance, strategy, and business development is expected to be a valuable asset as Elicio advances its ELI-002 program and immunotherapy platform through clinical development. Dr. Shah's primary focus will be to align financial and corporate strategies with the goal of bringing cancer immunotherapeutics to patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.